These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28671136)

  • 41. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.
    Koroshetz WJ; Jenkins BG; Rosen BR; Beal MF
    Ann Neurol; 1997 Feb; 41(2):160-5. PubMed ID: 9029064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From open to large-scale randomized cell transplantation trials in Huntington's disease: Lessons from the multicentric intracerebral grafting in Huntington's disease trial (MIG-HD) and previous pilot studies.
    Bachoud-Lévi AC
    Prog Brain Res; 2017; 230():227-261. PubMed ID: 28552231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
    Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
    Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers.
    Marshall J; White K; Weaver M; Flury Wetherill L; Hui S; Stout JC; Johnson SA; Beristain X; Gray J; Wojcieszek J; Foroud T
    Arch Neurol; 2007 Jan; 64(1):116-21. PubMed ID: 17210818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exercise effects in Huntington disease.
    Frese S; Petersen JA; Ligon-Auer M; Mueller SM; Mihaylova V; Gehrig SM; Kana V; Rushing EJ; Unterburger E; Kägi G; Burgunder JM; Toigo M; Jung HH
    J Neurol; 2017 Jan; 264(1):32-39. PubMed ID: 27747393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Body weight is a robust predictor of clinical progression in Huntington disease.
    van der Burg JMM; Gardiner SL; Ludolph AC; Landwehrmeyer GB; Roos RAC; Aziz NA
    Ann Neurol; 2017 Sep; 82(3):479-483. PubMed ID: 28779551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Participant withdrawal: challenges and practical solutions for recruitment and retention in clinical trials.
    Hadidi N; Lindquist R; Treat-Jacobson D; Swanson P
    Creat Nurs; 2013; 19(1):37-41. PubMed ID: 23600026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.
    Carlozzi NE; Miciura A; Migliore N; Dayalu P
    J Huntingtons Dis; 2014; 3(3):233-52. PubMed ID: 25300328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A double-blind clinical trial of isoniazid in Huntington disease.
    Perry TL; Wright JM; Hansen S; Thomas SM; Allan BM; Baird PA; Diewold PA
    Neurology; 1982 Apr; 32(4):354-8. PubMed ID: 6460947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate.
    Travessa AM; Rodrigues FB; Mestre TA; Ferreira JJ
    J Huntingtons Dis; 2017; 6(2):157-163. PubMed ID: 28671135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Social Withdrawal in Huntington's Disease: A Scoping Review.
    Gibson JS; Springer K
    J Huntingtons Dis; 2022; 11(1):17-24. PubMed ID: 35124657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perceived Effects of Neuropsychiatric Symptoms on Functional Status in Early-stage Huntington Disease.
    Gibson JS; Rhoten BA; Ridner SH; Claassen DO
    West J Nurs Res; 2022 Feb; 44(2):141-150. PubMed ID: 33543680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A pilot assessment of parental practices and attitudes regarding risk disclosure and clinical research involving children in Huntington disease families.
    Dure LS; Quaid K; Beasley TM
    Genet Med; 2008 Nov; 10(11):811-9. PubMed ID: 18941422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Participant Experiences in the Environmental Determinants of Diabetes in the Young Study: Common Reasons for Withdrawing.
    Lernmark B; Lynch K; Baxter J; Roth R; Simell T; Smith L; Swartling U; Johnson SB;
    J Diabetes Res; 2016; 2016():2720650. PubMed ID: 26682228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding the Relationship Between Perseveration, Comorbid Behavioral Symptoms, Motor Decline, Functional Decline, and Self-report Accuracy in Huntington Disease Can Help Inform Clinical Practice.
    Liu AM; Koppel E; Anderson KE
    Cogn Behav Neurol; 2023 Jun; 36(2):93-99. PubMed ID: 36633581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD.
    Williams J; Downing N; Vaccarino AL; Guttman M; Paulsen JS
    PLoS Curr; 2011 Aug; 3():RRN1254. PubMed ID: 21901173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.
    Banno H; Andrzejewski KL; McDermott MP; Murphy A; Majumder M; de Blieck EA; Auinger P; Cudkowicz ME; Atassi N
    J Huntingtons Dis; 2017; 6(4):371. PubMed ID: 28922164
    [No Abstract]   [Full Text] [Related]  

  • 59. What do we know about Late Onset Huntington's Disease?
    Chaganti SS; McCusker EA; Loy CT
    J Huntingtons Dis; 2017; 6(2):95-103. PubMed ID: 28671137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triheptanoin for the treatment of brain energy deficit: A 14-year experience.
    Mochel F
    J Neurosci Res; 2017 Nov; 95(11):2236-2243. PubMed ID: 28688166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.